ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

Abstract

Multidrug-resistant (MDR) bacterial infections are a serious threat to public health. Among the most alarming resistance trends is the rapid rise in the number and diversity of β-lactamases, enzymes that inactivate β-lactams, a class of antibiotics that has been a therapeutic mainstay for decades. Although several new β-lactamase inhibitors have been… (More)
DOI: 10.1038/nmicrobiol.2017.104

Topics

6 Figures and Tables

Cite this paper

@article{DurandRville2017ETX2514IA, title={ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii}, author={Thomas F Durand-R{\'e}ville and Satenig Y Guler and Janelle Comita-Prevoir and Brendan Chen and Neil Bifulco and Hoan K Huynh and Sushmita D. Lahiri and Adam B Shapiro and Sarah M. McLeod and Nicole M. Carter and Samir H Moussa and Camilo Velez-Vega and Nelson B. Olivier and Robert E. McLaughlin and Ning Gao and Jason Thresher and Tiffany Palmer and Beth Andrews and Robert A. Giacobbe and Joseph V. Newman and David E. Ehmann and Boudewijn L M de Jonge and John P. R. O'Donnell and John P. Mueller and Ruben Tommasi and Alita A Miller}, journal={Nature Microbiology}, year={2017}, volume={2} }